Reports Q4 revenue $61M, consensus $60.06M. “2023 was a defining year for Evolus. We achieved record market share as the fastest growing toxin in the U.S. for the third consecutive year, expanded our portfolio globally with the addition of an innovative late-stage line of facial fillers, and delivered continued improvement in operating income performance,” said David Moatazedi, President and Chief Executive Officer of Evolus. “We expect to be profitable1 for the fourth quarter of 2024 and the full year 2025.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on EOLS:
- EOLS Upcoming Earnings Report: What to Expect?
- Evolus upgraded to Overweight from Equal Weight at Barclays
- Evolus Stock (NASDAQ:EOLS) Spikes; Analysts See Significant Upside
- Evolus sees FY24 revenue $255M-$265M, consensus $253.27M
- Evolus sees Q4 revenue $61M, consensus $56.97M
Questions or Comments about the article? Write to editor@tipranks.com